Synergy Pharmaceuticals Inc (NASDAQ:SGYP) Stock Paying Off, for Short-Sellers

Synergy Pharmaceuticals Inc (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stock is continuing the slide that began on Tuesday after the company released their Q2 financials. This morning SGYP stock broke through the $3 level on volumes almost four times their normal average. Wednesday, Synergy posted a Q2 net loss of (-$73.9) million or (-$0.33) per share. Analysts were expecting a loss of only (-$0.25).

Synergy stock chart:

Synergy Pharmaceuticals Inc (NASDAQ:SGYP)
One month SGYP stock price chart

Trulance is Synergy Pharmaceuticals Inc (NASDAQ:SGYP)’s main sales generator. The drug addresses chronic idiopathic constipation and its sales performance exceeded projections. More than 12,600 TRULANCE prescriptions have been filled and total monthly prescription volume had an average increase of more than 182% month-over-month. At the end of the second quarter, more than half of new TRULANCE prescriptions filled since launch were coming from new patients not previously on a branded prescription treatment, and 45% were patients that converted from other branded prescription treatments.

Gary S. Jacob, Ph.D., Chairman and CEO of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stated ““The first half of 2017 was a truly transformative period for Synergy, as we transitioned into a commercial organization and launched our first product, TRULANCE, in the U.S. for the treatment of adults with chronic idiopathic constipation (CIC). We are pleased with the execution of our commercial strategy, and the strong initial demand for TRULANCE, reinforcing the need for new treatment options for patients suffering from CIC. And we are making significant progress in ensuring broad access to TRULANCE, highlighted by a number of favorable early decisions from key national payers.”

Synergy Pharmaceuticals Numbers

Although their featured drug, TRULANCE, seems to be selling well in the market, investors have been selling off SGYP stock. YTD, SGYP shares are down around 50% and down over 33% for the year. Currently the shares are trading within 2.5% of their 52-week low of $2.91. No doubt some of the downward pressure on SGYP stock is the large percent of the float held by short-sellers – over 27%. Still, analysts have given SGYP stock a consensus target price of $10.89.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SGYP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) Stock Continues Trend

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) stock plunged 12.50% in Thursday’s trading session as investors reacted to a disappointing second quarter earnings report. A net loss of (-$27.5) million compared to (-$17.5) million reported a year earlier appears to have spooked the market thus fuelling the sell-off wave.

One month Aralez stock chart:

Stock Performance

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) stock is currently trading at all-time lows after disappointing Q2 earnings. The stock has  been on a strong downtrend since late last year.

The stock currently has a negative net margin of 133.92% and a negative return on equity of 66.74%. A number of analysts have already initiated coverage of the stock with the majority of them rating the stock as a ‘sell’. ValuEngine lowered its rating on the stock to a ‘strong sell’ from a ‘sell’.

Aralez Pipeline

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) is a global specialty pharmaceutical focused on the delivery of meaningful products for improving patients’ lives. The company generates shareholder value by acquiring, developing and commercializing products in cardiovascular, pain and other specialty areas. Its lead products include Fibricor, Cambia Fiorinal, and Fiorinal C.

During the second quarter, Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced the commercial launch of Zontivity which is indicated for the treatment of peripheral artery disease in patients with a history of post-myocardial history. A team of 75 sales representative is currently marketing the drug

“We are also delighted with the strength of the early launch metrics for Zontivity® and are pleased that, within weeks of our national launch we have already reached all-time high prescription levels,” said CEO Adrian Adams.

Cost Saving Push

Aralez reported revenues of $27.6 million for the second quarter up from $12.6 million reported a year earlier. The cost of product revenue dropped to $2.9 million from $3.4 million because of $0.8 million in inventory step-up costs associated with the Tribute merger.

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) restructuring is gaining traction as the company continues to explore ways of reducing its costs of operations. In the second quarter, the company reduced its U.S sales force by 32% having also implemented a cost savings program designed to preserve financial flexibility. The company exited Q2 with $55 million in cash and cash equivalent which it says is sufficient to finance operations over the next 12 months.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARLZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Neothetics Inc (NASDAQ:NEOT) Tumbles To 52-Week Low

Neothetics Inc (NASDAQ:NEOT)

Shares of Neothetics Inc (NASDAQ:NEOT) tumbled 18.04% after the company reported second quarter financial results that fell short of Wall Street expectations. The selloff came on the clinical stage pharmaceutical company reporting a wider than expected second quarter net loss of (-$2.8) million compared to (-$2.7) million reported a year ago.

Neothetics Inc (NASDAQ:NEOT)
One month NEOT stock price chart

Stock Performance

Thursday’s sell off pushed Neothetics Inc (NASDAQ:NEOT) on the brink of its 52 week low of $0.30 as it continues to trade in a tight $0.30-$0.46 trading range. Neothetics sentiments turned sour early last month after the stock gapped lower from highs of $2.3 a share to current lows of $0.37 a share.

The stock continues to trade below its 20 days moving average having also tanked more than 60% below its 50-day moving average. The stock is currently trading at all-time lows having tanked from highs of $2.6 a share as of June.

The clinical stage pharmaceutical develops therapeutics for fat reduction and body contouring. Its lead product is LIPO-202, an injectable formulation for the reduction of localized fat deposits under the chin as well as for the deduction of central abdominal reduction.

The board of directors recently approved plans to initiate acquisitions as well as partnerships as part of an effort that seeks to expand Neothetics Inc. (NASDAQ:NEOT) footprint into new areas of growth. Pursuit of strategic alliance is also geared towards discovering and maximizing shareholder value. The company has already engaged the services of Oppenheimer and Co as its financial advisor for the new initiative.

Neothetics Inc (NASDAQ:NEOT) has also announced plans to streamline its operations as it seeks to preserve capital and cash resources. Plans are underway to trim the company’s workforce from six to two as the firm seeks to reduce its wage bill.

Q2 Earnings

The cost reduction drive follows an increase in research and development expenses in the second quarter to $1.6 million from $1.4 million. However, for the six months ended June 30, 2016, R&D expenditure dropped to $3.1 million from $4.7 million a year earlier. Neothetics attributes the decline to completion of a majority of close out activities for AbCONTOUR1 and AbCONTOUR2 U.S. Phase 3 clinical trials

Neothetics Inc (NASDAQ:NEOT) General and administrative expenses soared to $1.3 million from $1.1 million a year earlier. However, for the six months ended June 30, 2017, total general administrative expenses dropped to $2.7 million from $3.6 million a year earlier. The company attributes the decline to reduced personnel expenses.

Neothetics Inc. (NASDAQ:NEOT) exited the second quarter with cash and cash equivalent of $7.6 million compared to $11.5 million as of December 31, 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NEOT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Avinger Inc (NASDAQ:AVGR) Shares Drop on Revenue Concerns

Avinger Inc (NASDAQ:AVGR) Stock Tanks As Q2 Revenue Drops 47%

Avinger Inc (NASDAQ:AVGR) stock plunged 11.28% after the company reported second quarter financial results that fell short of Wall Street expectations. The company reported a net loss of $11.3 million, a disappointment compounded by a 47% decline in total revenue.

Wednesday’s sell-off of Avinger stock pushed it to near all-time lows as it continues to trade in a strong downtrend. Avinger stock continues to trade in a tight $0.40-$0.45 trading range and closing in on its 52-week lows of $0.35 a share.

Avinger stock, one-month price chart:

Avinger Inc (NASDAQ:AVGR)
One month chart for Avinger stock

Avinger Inc (NASDAQ:AVGR) is medical stage company that manufactures and sells image-guided and catheter-based systems for use in the treatment of peripheral arterial disease. The company also owns a proprietary lumivascular platform that integrates optical coherence tomography with catheters to provide real-time imaging during treatment.

Jeff Soinski, CEO, says they have made significant progress on the development of the next generation Pantheris Catheters. The next generation devices are expected to expand the company’s target market starting in 2018.

“Following our strategic reorganization in April, I’m pleased with how our more focused commercial organization has come together to drive utilization within our installed base of Lumivascular accounts,” said Mr. Soinski.

Avinger’s Disappointing Q2 Results

Total revenue in the second quarter came in at $2.5 million down by 47% compared to the second quarter of 2016. Gross margin dropped to -59% from 22% as of last year. Avinger Inc (NASDAQ:AVGR) attributes the decline to a $2.3 million charge for excesses and obsolete inventories.

In line with ongoing plans to reduce cash burn, Avinger Inc. successfully reduced its operating expenses to $9.8 million compared to $13.3 million as of Q2 2016. The decline was because of a decrease in sales and marketing expenditure this year compared to last year.

Avinger Inc (NASDAQ:AVGR) exited the second quarter with cash and cash equivalents of $14 million compared to $23 million as of March 31, 2017. Thanks to ongoing organizational restructuring, the company expects cash utilization to drop to $7 million per quarter compared to an average of 13.4 million per quarter as of last year.

Class Action Lawsuit

Separately, Avinger Inc (NASDAQ:AVGR) is the subject of a class-action lawsuit over claims its executives violated federal securities laws. Complaints allege that the Registration Statement and Prospectus filed for Avinger’s stock IPO contained false and misleading statements.

Law firms allege that Avinger failed to disclose that it did not have adequate marketing personnel for its lumivascular platform – a deficiency that has led to lackluster sales.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVGR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Novavax, Inc. (NASDAQ:NVAX) Stock Move Reflects Expectations

Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) stock price gained nearly 2% the day after the biotechnology company released their Q2 2017 financial results. Novavax reported a Q2 2017 quarterly loss of (-$44.5), on $6.7 million in revenue, or (-$0.16) per share. Results basically met street expectations. Novavax stock closed today at $0.99 on normal volume. Novavax stock price chart:

Novavax, Inc. (NASDAQ:NVAX)
One month stock price chart for NVAX

Gaithersburg, MD-based Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company that develops prducts, including vaccines, to prevent a broad range of infectious diseases. The company utilizes recombinant nanoparticles and Matrix-M™ adjuvant technology. Their product pipeline targets a variety of infectious diseases, with clinical vaccine candidates for respiratory syncytial virus (RSV) and Ebola virus (EBOV), and preclinical programs for Zika virus (ZIKV), seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

Novavax Financials

Research and development expenses decreased 40% to $39.3 million in the second quarter of 2017, compared to $64.9 million for the same period in 2016. The decrease was primarily due to reduced costs associated with the clinical trials and development activities of Novavax’s RSV F Vaccine and lower employee-related costs.

SG&A expenses decreased 37% to $8.9 million in Q2 2017, compared to $14.1 million for the same period in 2016. The decrease was primarily due to lower professional fees for pre-commercialization activities and lower employee-related costs.

Novavax stock has been a poor performer. YTD, Novavax shares have been down over 21% and are down over 86% for the year. Per share losses have been expanding ever since 2012 when Novavax posted a per share loss of (-$0.22). By 2016 that loss had broadened to (-$1.03). Likewise, dilution has been a real issue for stockholders. The number of outstanding shares has more than doubled since 2012 when the number was posted at 131.73 million. By 2016 that number was over 270 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NVAX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

OpGen Inc (NASDAQ:OPGN) Stock Follows Trend

OpGen Inc (NASDAQ:OPGN)

OpGen Inc (NASDAQ:OPGN) stock was down $0.02 at the close of today’s trading as investors absorbed its Q2 financial report after yesterday’s market close. OpGen Inc (NASDAQ:OPGN) reported a Q2 (-$4.2) million net loss compared with $5.1 million for Q2 2016. Net loss for the six months ended June 30, 2017 was $9.2 million compared with $9.6 million for the six months ended June 30, 2016.

OpGen Inc (NASDAQ:OPGN)
One month OPGN Stock Price Chart

OpGen’s total Q2 revenue was $0.7 million compared with $1.2 million for Q2 2016. Total revenue for the six months ended June 30, 2017 was $1.5 million compared with $2.3 million for the six months ended June 30, 2016.

OpGen Inc (NASDAQ:OPGN) Q2 operating expenses were $4.9 million compared with $6.2 million for the same period in 2016. Operating expenses for the six months ended June 30, 2017 were $10.6 million compared with $11.8 million for the six months ended June 30, 2016.

Cash and cash equivalents were $0.2 million as of June 30, 2017 compared with $4.1 million as of December 31, 2016. Subsequent to the close of Q2, OpGen Inc (NASDAQ:OPGN)  raised net proceeds of $8.7 million in a public offering.

OpGen stock is sitting on its 52-week lows of $0.30. OpGen shares have lost over 72% YTD, and are down over 85% for the year. Dilution has been an issue for shareholders. In 2014 10.72 million shares were outstanding but by 2016 that number ballooned to 17.67 million. Sales did improve from 2015 when OpGen posted a sales figure of $3.2 million which was followed in 2016 by a figure of $4.0 million. Meanwhile, per share losses have been the norm. For 2016 each share lost (-$1.10).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN stock and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Why Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Stock Broke Resistance

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock price is up over 22% after the biotechnology company announced positive interim results for its drug candidate, ACH-4471. Also today the company reported financial results for the most recent quarter and six months. By 12:40 PM EST, ACHN shares had a volume of over 20 million shares, far exceeding their daily average of 1.5 million.

As of market close yesterday, ACHN shares were down YTD, but after news of the interim clinical trial results, ACHN stock gapped up to open at $4.70 then proceeded to blast through resistance just above $5.00. Shares of ACHN then hit an inter-day high of $5.66 before sellers came in and pushed the shares back below the $5.00 level. Analysts have given ACHN stock a price target of $6.75.

ACHN stock chart:

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Six month stock price chart for Achillion ACHN

Achillion Pharmaceuticals Reports Interim Results

Achillion Pharmaceuticals released interim data from ongoing ACH-4471 trials that indicated the drug candidate had achieved clinically meaningful complement inhibition and demonstrated a favorable tolerability profile with no reports of clinically meaningful increases in liver enzymes. In this initial set of data, ACH-4471 improved LDH, hemoglobin, fatigue score, and other measures of response including PNH clone size. These interim results support Achillion’s global expansion plans for PNH clinical trials.

Achillion Pharmaceuticals Financial Report

For Q2 2017, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported a net loss of (-$22.5) million or (-$0.16) per share, compared with a net loss of $18.5 million or $0.14 per share for the second quarter of 2016. Cash, cash equivalents, marketable securities, and interest receivable as of June 30, 2017 were $369.9 million. Research and development expenses were $18.3 million compared with $14.2 million for the same period of 2016. The increase was primarily due to increased ACH-4471 clinical trial costs as well as increased manufacturing costs for ACH-5228. SG&A expenses were $5.4 million, compared with $5.2 million for Q2 2016. The increase was primarily due to increased legal and consulting fees.

For the six months ended June 30, 2017, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s net loss was $42.7 million, compared to a net loss of $36.6 million for the first half of 2016. R&D totaled $33.8 million, compared with $27.4 million for the same period in 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACHN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Can Bioline RX Ltd (NASDAQ:BLRX) Sustain Momentum?

Bioline RX Ltd (NASDAQ:BLRX)

Bioline RX Ltd (NASDAQ:BLRX) has announced its second quarter’s financial results and the stock rose by 3.51% to close the day at $1.18 a share. The clinical-stage biopharmaceutical firm also announced it embarked on plans to start a Phase III study on BL-8040 after holding a meeting with the U.S. Food and Drug Administration.

Bioline RX Ltd (NASDAQ:BLRX)
One month Bioline stock price chart

An investment in the biopharmaceutical firm was made by BVF Partners, currently its biggest shareholder. This increased the stake of BVF Partners in BioLineRx to 24.9%. The new investment by BVF Partners, which is valued at $9.6 million, came at a per-unit price of $1.13

“We are also pleased to have received a strong vote of confidence from BVF Partners last month. The $9.6 million direct investment we received will allow us to accelerate the development of our clinical programs,” Bioline RX Ltd (NASDAQ:BLRX)’s Chief Executive Officer, Philip Serlin, said.

Research and development

In the financial results, expenses arising from research and development for the second quarter were $4 million. This was a 48.2% increase from the $2.7 million in a similar quarter a year ago. These expenses resulted from spending on BL-8040 and AGI-134. Expenses from sales and marketing activities for the June quarter amounted to $0.3 million and this was largely the same as what was incurred a year ago in a similar period.

Administrative expenses

Expenses attributed to general and administrative activities amounted to $0.8 million and this was almost the same as a similar quarter in 2016. Net financial income for Bioline RX Ltd (NASDAQ:BLRX) also increased in this second quarter to $0.3 million compared to last year’s second quarter net financial income which was $0.1 million.

In the second quarter the operating loss increased to $5.2 million compared to the $3.9 million recorded in a similar quarter last year. Net loss for the second quarter was $4.9 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BLRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Galena Biopharma Inc (NASDAQ:GALE) Drops Big on Merger Announcement

Galena Biopharma Inc (NASDAQ:GALE)

Galena Biopharma Inc (NASDAQ:GALE) stock is off over 27% after the company announced merger plans with privately-held SELLAS Life Sciences Group Ltd in an all-stock deal. The new company will be named SELLAS Life Science Group, Inc. Bothe Galena and SELLAS focus on developing late-stage, novel cancer treatments.

In late January, Galena Biopharma Inc (NASDAQ:GALE) was trading under $2.00 after having been above $45 earlier that same month and class-action law firms were seeking plaintiffs. They alleged that Galena made false and/or misleading statements and/or failed to disclose that: (1) Galena’s sales of Abstral were based on unsustainable sales and marketing practices; (2) such sales and marketing practices could subject Galena to a criminal investigation; and (3) consequently, Galena’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

Subsequently, Galena Biopharma Inc (NASDAQ:GALE) announced that they were seeking strategic alternatives that would maximize shareholders value. As time went on, GALE shares slid to less than $1.

Under the terms of the merger agreement, existing SELLAS shareholders will receive newly issued shares of Galena common stock. Assuming that the merger is consummated, Galena stock and warrant holders are expected to own approximately 32.5%, and SELLAS shareholders will own approximately 67.5% of the combined.

The SELLAS board of directors unanimously approved the terms of the merger and a majority of SELLAS shareholders have voted in favor of the transaction. The proposed merger is expected to close in Q4 2017, subject to the formal approval of Galena Biopharma Inc (NASDAQ:GALE) stockholders and other customary closing conditions.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $GALE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Why Bioamber Inc (NYSE:BIOA) Stock is Plummeting

Bioamber Inc (NYSE:BIOA)

Bioamber Inc (NYSE:BIOA) stock is down over 45% today after the company announced an underwritten public offering. The offering will include 14,666,667 shares of common stock with warrants attached that could, if exercised, double that figure. Excluding stock options, warrants, and employee-based bonus plans, as of June 30, 2017, the number of outstanding shares was 37,142,830. Existing shareholders will have their equity diluted by around 29%, excluding other potential share sales or option/warrant exercises.

Shareholders of Bioamber Inc (NYSE:BIOA) have had a rough week. On Friday, August 4, BIOA shares lost over 32%. On Monday that was followed by shares dropping almost 35%, and today shares have lost over 45%. YTD, shares have dropped over 85% and have obliterated the previous 52-week low of $0.96 – at last glance, BIOA shares are trading around $0.53. Volume for the biotech company is very heavy – over sixty times the 30-day, daily average.

Bioamber Inc (NYSE:BIOA) is an industrial biotechnology company. It produces and sells bio-succinic acid to various chemical market customers in North America. Bioamber’s proprietary technology processes combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into chemicals that can act as replacements for petroleum-derived chemicals. The company’s bio-succinic acid is used in various applications, including plasticizers, polyurethanes, personal care products, resins and coatings.

Bioamber Inc (NYSE:BIOA) priced the underwritten public offering which includes 14,666,667 shares of common stock of the Company and warrants to purchase up to 14,666,667 shares of common stock of the Company at a price to the public of $0.75 per share and associated warrant. The warrants have an exercise price of $0.75 and a term of five (5) years, exercisable upon the date of issuance. The aggregate gross proceeds to the Company (assuming no exercise of the warrants) are US$11 million , before deducting underwriting discounts and commissions and estimated offering expenses.

Bioamber Inc (NYSE:BIOA) has granted to the underwriters a 30-day over-allotment option to purchase up to an additional 2.2 million shares of common stock and/or warrants to purchase up to 2.2 million shares of common stock. Potential proceeds to Bioamber are approximately $1.65 million (assuming no exercise of the warrants) before deducting underwriting discounts and commissions and estimated offering expenses. In the event the Over-Allotment Option is exercised in full, the aggregate gross proceeds to the Company (assuming no exercise of the warrants) will be approximately $12.65 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BIOA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.